Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
4°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
459.00
-3.58 (-0.77%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Small- To Mid-Cap Biotech Trades Poised For Gains
February 01, 2025
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief
January 31, 2025
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Product Safety
What's going on in today's session: S&P500 movers
January 31, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via
Chartmill
Top S&P500 movers in Friday's session
January 31, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)
January 30, 2025
Via
Benzinga
Is Vertex Pharmaceuticals Stock a Buy in 2025?
January 26, 2025
Via
The Motley Fool
How Is The Market Feeling About Vertex Pharmaceuticals?
January 15, 2025
Via
Benzinga
Vertex Pharmaceuticals Stock Soars As Non-Opioid Pain Treatment Gets FDA Nod
January 31, 2025
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain.
Via
Talk Markets
Topics
Stocks / Equities
Exposures
Product Safety
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter
January 31, 2025
The company won Food and Drug Administration approval for its non-opioid painkiller pill on Thursday.
Via
Investor's Business Daily
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
January 31, 2025
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy.
Via
Benzinga
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday
January 31, 2025
Via
Benzinga
Friday's pre-market session: top gainers and losers in the S&P500 index
January 31, 2025
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.
Via
Chartmill
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
January 10, 2025
Via
Benzinga
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
January 30, 2025
The first-in-class drug had suffered a setback in December.
Via
Investor's Business Daily
Exposures
Product Safety
This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
January 30, 2025
Via
Benzinga
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
January 25, 2025
Via
The Motley Fool
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
January 24, 2025
Via
The Motley Fool
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
January 23, 2025
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via
MarketBeat
Exposures
Product Safety
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
January 21, 2025
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
January 20, 2025
Via
Benzinga
3 Unstoppable Stocks to Buy in 2025
January 18, 2025
Via
The Motley Fool
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
January 16, 2025
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.
Via
Benzinga
Vertex's Pain Drug: Big Pharma's Next Major Success?
January 16, 2025
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
Via
MarketBeat
Exposures
Product Safety
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
January 16, 2025
Via
The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
January 14, 2025
Via
Benzinga
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
January 14, 2025
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.
Via
Benzinga
Exposures
Product Safety
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
January 14, 2025
Via
The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2025
January 13, 2025
Via
The Motley Fool
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
January 10, 2025
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Exposures
Artificial Intelligence
Political
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.